RxDoctor Payments Data

Jamie Ham, NP

Family · Goldsboro, NCNPI 1477912632

Payments from drug & device makers

$808in general payments, 2019–2025

Across 46 payments — averaging $17.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$354
  • AbbVie$141
  • Abbott$64
  • Dexcom, Inc.$49
  • Insulet Corporation$44
  • Boehringer Ingelheim$37
  • plus $119 from 7 others

What the payments were for

  • Food & beverage$808100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$808 in reported general payments places this provider in the 65th percentile of 4,522 family providers in North Carolina.

See all family providers in North Carolina

Medicare billing

Part B allowed, 2024
$96,689
Medicare patients
289
Services billed
2,932

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide77$94,889
JardianceEmpagliflozin59$65,573
EliquisApixaban76$60,360
XareltoRivaroxaban39$35,787
RybelsusSemaglutide24$26,620
TrulicityDulaglutide21$19,953
JanuviaSitagliptin Phosphate12$15,419
Repatha SureclickEvolocumab12$15,146
MounjaroTirzepatide12$14,650
FarxigaDapagliflozin Propanediol16$11,069
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog18$10,143
Trelegy ElliptaFluticasone/Umeclidin/Vilanter11$8,912
MyrbetriqMirabegron15$8,695
Breo ElliptaFluticasone/Vilanterol15$6,080
Tresiba Flextouch U-100Insulin Degludec11$5,292

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$354$121,509101 claims
Boehringer IngelheimJardiance$37$65,57359 claims
PfizerEliquis$15$60,36076 claims
Lilly USA, LLCTrulicity, Mounjaro$14$34,60333 claims
GSKTrelegy Ellipta, Breo Ellipta$14$14,99226 claims
AbbVieSynthroid$141$2,91845 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 4,522 family providers in North Carolina.

Other family in Goldsboro

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →